{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:17:52Z","timestamp":1779203872480,"version":"3.51.4"},"reference-count":50,"publisher":"IMR Press","issue":"2","license":[{"start":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T00:00:00Z","timestamp":1675641600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Cardiovasc. Med."],"abstract":"<jats:p>Background: Atrial fibrillation (AF) is observed in arterial hypertension, heart failure, ischemic heart disease, and pulmonary pathology, particularly, chronic obstructive pulmonary disease (COPD). COPD in turn is a risk factor for developing these cardiovascular diseases and various arrhythmias. In the coronavirus disease (COVID) situation, such comorbid patients are the most vulnerable group with a high risk of adverse outcomes. The relevance of the relationship between COPD and coronavirus infection is explained by the similarity of clinical and pathophysiological manifestations, creating more difficulties in diagnosing and determining rational treatment. The aim of the current study is to explore the role COPD plays in the onset and progression of AF, especially in the situation of COVID-19. Methods: We searched PubMed databases and included studies with information on comorbid patients suffering from COPD and AF, as well as similar patients in the context of COVID-19. Results: A modern view on the problem of comorbidity of COPD and AF is presented. In the presence of cardiorespiratory comorbidity, symptoms of mutual worsening of the clinical course are observed, due to the commonality of some links of pathogenesis, including hypoxia, hemodynamic disturbances, activation of the sympathoadrenal system, systemic inflammation, and development of fibrosis, leading to myocardial remodeling, a decrease in the effectiveness of the therapy, and a worsening prognosis, especially in the context of COVID-19. Conclusions: The results of a study of the features of the pathogenesis and course of AF in COPD are presented, as well as the formation and progression of this comorbid pathology in the context of the COVID-19 pandemic.<\/jats:p>","DOI":"10.31083\/j.rcm2402051","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T07:59:39Z","timestamp":1676015979000},"source":"Crossref","is-referenced-by-count":5,"title":["Features of Atrial Fibrillation Pathogenesis and Prognosis in Chronic Obstructive Pulmonary Patients during the COVID-19 Pandemic"],"prefix":"10.31083","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1811-5108","authenticated-orcid":true,"given":"Lusine G.","family":"Hazarapetyan","sequence":"first","affiliation":[{"name":"Department of Cardiology, Yerevan State Medical University named after Mkitar Heratsi, 0025 Yerevan, Armenia"},{"name":"Department of Arrhythmias, Scientific Research Institute of Cardiology named after Levon Hovhannisyan, 0014 Yerevan, Armenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6513-6772","authenticated-orcid":true,"given":"Parounak H.","family":"Zelveian","sequence":"first","affiliation":[{"name":"Department of Cardiology, Yerevan State Medical University named after Mkitar Heratsi, 0025 Yerevan, Armenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9628-106X","authenticated-orcid":true,"given":"Svetlana V.","family":"Grigoryan","sequence":"first","affiliation":[{"name":"Department of Cardiology, Yerevan State Medical University named after Mkitar Heratsi, 0025 Yerevan, Armenia"},{"name":"Department of Arrhythmias, Scientific Research Institute of Cardiology named after Levon Hovhannisyan, 0014 Yerevan, Armenia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16242","published-online":{"date-parts":[[2023,2,6]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Singh D, Mathioudakis AG, Higham A. Chronic obstructive pulmonary disease and COVID-19: interrelationships. Current Opinion in Pulmonary Medicine. 2022; 28: 76\u201383.","DOI":"10.1097\/MCP.0000000000000834"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Fekete M, Szarvas Z, Fazekas-Pongor V, Feher A, Dosa N, Lehoczki A, et al. COVID-19 infection in patients with chronic obstructive pulmonary disease: From pathophysiology to therapy. Mini-review. Physiology International. 2022. (online ahead of print)","DOI":"10.1556\/2060.2022.00172"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Baigent C, Windecker S, Andreini D, Arbelo E, Barbato E, Bartorelli AL, et al. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis. Cardiovascular Research. 2022; 118: 1385\u20131412.","DOI":"10.1093\/cvr\/cvab342"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. The Journal of the American Medical Association. 2020; 323: 1061\u20131069.","DOI":"10.1001\/jama.2020.1585"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Medicine. 2020; 46: 846\u2013848.","DOI":"10.1007\/s00134-020-05991-x"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Shchikota AM, Pogonchenkova IV, Turova EA, Rassulova MA, Gumenyuk SA. Chronic obstructive pulmonary disease and COVID-19: topical issues. Pulmonologiya. 2020; 30: 599\u2013608.","DOI":"10.18093\/0869-0189-2020-30-5-599-608"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Hansen ESH, Moeller AL, Backer V, Andersen MP, Kober L, Kragholm K, et al. Severe outcomes of COVID-19 among patients with COPD and asthma. ERJ Open Research. 2021; 7: 594\u20132020.","DOI":"10.1183\/23120541.00594-2020"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Guan W, Liang W, Zhao Y, Liang H, Chen Z, Li Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. The European Respiratory Journal. 2020; 55: 2000547.","DOI":"10.1183\/13993003.01227-2020"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. The Journal of the American Medical Association. 2020; 323: 1775\u20131776.","DOI":"10.1001\/jama.2020.4683"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016; 18: 1609\u20131678.","DOI":"10.5603\/KP.2016.0172"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Tarride J, Quinn FR, Blackhouse G, Sandhu RK, Burke N, Gladstone DJ, et al. Is Screening for Atrial Fibrillation in Canadian Family Practices Cost-Effective in Patients 65 Years and Older? The Canadian Journal of Cardiology. 2018; 34: 1522\u20131525.","DOI":"10.1016\/j.cjca.2018.05.016"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014; 129: 837\u2013847.","DOI":"10.1161\/CIRCULATIONAHA.113.005119"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Morin DP, Bernard ML, Madias C, Rogers PA, Thihalolipavan S, Estes NAM. The State of the Art: Atrial Fibrillation Epidemiology, Prevention, and Treatment. Mayo Clinic Proceedings. 2016; 91: 1778\u20131810.","DOI":"10.1016\/j.mayocp.2016.08.022"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Bassand J, Accetta G, Camm AJ, Cools F, Fitzmaurice DA, Fox KAA, et al. Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. European Heart Journal. 2016; 37: 2882\u20132889.","DOI":"10.1093\/eurheartj\/ehw233"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS. Revista Espanola De Cardiologia. 2017; 70: 50.","DOI":"10.1016\/j.rec.2016.11.033"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Peters SAE, Woodward M. Established and novel risk factors for atrial fibrillation in women compared with men. Heart. 2019; 105: 226\u2013234.","DOI":"10.1136\/heartjnl-2018-313630"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC). European Heart Journal. 2016; 37: 2893\u20132962.","DOI":"10.1093\/eurheartj\/ehw210"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Triposkiadis F, Pieske B, Butler J, Parissis J, Giamouzis G, Skoularigis J, et al. Global left atrial failure in heart failure. European Journal of Heart Failure. 2016; 18: 1307\u20131320.","DOI":"10.1002\/ejhf.645"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Dan G, Iliodromitis K, Scherr D, Mar\u00edn F, Lenarczyk R, Estner HL, et al. Translating guidelines into practice for the management of atrial fibrillation: results of an European Heart Rhythm Association Survey. Europace. 2018; 20: 1382\u20131387.","DOI":"10.1093\/europace\/euy094"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Proietti M, Mairesse GH, Goethals P, Scavee C, Vijgen J, Blankoff I, et al. A population screening programme for atrial fibrillation: a report from the Belgian Heart Rhythm Week screening programme. Europace. 2016; 18: 1779\u20131786.","DOI":"10.1093\/europace\/euw069"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Tischer TS, Schneider R, Lauschke J, Diedrich D, Kundt G, B\u00e4nsch D. Prevalence of atrial fibrillation and the HATCH score: Intensified monitoring of patients with high HATCH score. Herz. 2015; 40: 803\u2013808.","DOI":"10.1007\/s00059-015-4305-4"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Liao J, Chao T, Liu C, Wang K, Chen S, Lin Y, et al. Incidence and risk factors for new-onset atrial fibrillation among patients with end-stage renal disease undergoing renal replacement therapy. Kidney International. 2015; 87: 1209\u20131215.","DOI":"10.1038\/ki.2014.393"},{"key":"ref23","unstructured":"Khidirova LD, Yakhontov DA, Zenin SA. Atrial fibrillation in combination with arterial hypertension and extracardiac comorbital pathology. Bulletin of New Medical Technologies. 2019; 3: 7\u201310."},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Romiti GF, Corica B, Pipitone E, Vitolo M, Raparelli V, Basili S, et al. Prevalence, management and impact of chronic obstructive pulmonary disease in atrial fibrillation: a systematic review and meta-analysis of 4,200,000 patients. European Heart Journal. 2021; 42: 3541\u20133554.","DOI":"10.1093\/europace\/euab116.143"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Grinevich VB, Gubonina IV, Doshchitsin VL, Kotovskaya YV, Kravchuk YA, Ped VI, et al. Management of patients with comorbidity during novel coronavirus (COVID-19) pandemic. National Consensus Statement 2020. Cardiovascular Therapy and Prevention. 2020; 19: 2630.","DOI":"10.15829\/1728-8800-2020-2630"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Simons SO, Elliott A, Sastry M, Hendriks JM, Arzt M, Rienstra M, et al. Chronic obstructive pulmonary disease and atrial fibrillation: an interdisciplinary perspective. European Heart Journal. 2021; 42: 532\u2013540.","DOI":"10.1093\/eurheartj\/ehaa822"},{"key":"ref27","unstructured":"Agust A, Celli BR, Chen R, Criner G, Frith P, Halpin D, et al. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI\/WHO workshop report. 2018. Available at: http:\/\/www.goldcopd.org (Accessed: 1 August 2022)."},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Hashemi SY, Momenabadi V, Faramarzi A, Kiani A. Trends in burden of chronic obstructive pulmonary disease in Iran, 1995-2015: findings from the global burden of disease study. Archives of Public Health. 2020; 78: 45.","DOI":"10.1186\/s13690-020-00426-x"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Potpara TS, Lip GYH, Dagres N, Crijns HJMG, Boriani G, Kirchhof P, et al. Cohort profile: the ESC EURObservational Research Programme Atrial Fibrillation III (AF III) Registry. European Heart Journal - Quality of Care & Clinical Outcomes. 2021; 7: 229\u2013237.","DOI":"10.1093\/ehjqcco\/qcaa050"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Konecny T, Park JY, Somers KR, Konecny D, Orban M, Soucek F, et al. Relation of chronic obstructive pulmonary disease to atrial and ventricular arrhythmias. The American Journal of Cardiology. 2014; 114: 272\u2013277.","DOI":"10.1016\/j.amjcard.2014.04.030"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Stewart S, Hart CL, Hole DJ, McMurray JJV. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew\/Paisley study. The American Journal of Medicine. 2002; 113: 359\u2013364.","DOI":"10.1016\/S0002-9343(02)01236-6"},{"key":"ref32","unstructured":"Gyntelberg F, Hein HO, Suadicani P. The Copenhagen Male Study. Ugeskr Laeger. 2004; 166: 1444\u20131448."},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Shibata Y, Watanabe T, Osaka D, Abe S, Inoue S, Tokairin Y, et al. Impairment of pulmonary function is an independent risk factor for atrial fibrillation: the Takahata study. International Journal of Medical Sciences. 2011; 8: 514\u2013522.","DOI":"10.7150\/ijms.8.514"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Chen X, Lin M, Wang W. The progression in atrial fibrillation patients with COPD: a systematic review and meta-analysis. Oncotarget. 2017; 8: 102420\u2013102427.","DOI":"10.18632\/oncotarget.22092"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Liu X, Chen Z, Li S, Xu S. Association of Chronic Obstructive Pulmonary Disease With Arrhythmia Risks: A Systematic Review and Meta-Analysis. Frontiers in Cardiovascular Medicine. 2021; 8: 732349.","DOI":"10.3389\/fcvm.2021.732349"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Ovsyannikov ES, Avdeev SN, Budnevskiy AV, Drobysheva ES, Kravchenko AY. COVID-19 and chronic obstructive pulmonary disease: what is known about the unknown. Tuberculosis and Lung Diseases. 2021; 99: 6\u201315.","DOI":"10.21292\/2075-1230-2021-99-2-6-15"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Kunisaki KM, Dransfield MT, Anderson JA, Brook RD, Calverley PMA, Celli BR, et al. Exacerbations of Chronic Obstructive Pulmonary Disease and Cardiac Events. A Post Hoc Cohort Analysis from the SUMMIT Randomized Clinical Trial. American Journal of Respiratory and Critical Care Medicine. 2018; 198: 51\u201357.","DOI":"10.1164\/rccm.201711-2239OC"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Chen C, Lin C, Hao W, Chiu C, Fang Y, Liu J, et al. Association between chronic obstructive pulmonary disease and ventricular arrhythmia: a nationwide population-based cohort study. NPJ Primary Care Respiratory Medicine. 2021; 31: 8.","DOI":"10.1038\/s41533-021-00221-3"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Swenson ER. Sympathetic Nervous System Activation and Vascular Endothelial Function With Chronic Hypoxia. Circulation Research. 2020; 127: 247\u2013248.","DOI":"10.1161\/CIRCRESAHA.120.317114"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Giuriato G, Paneroni M, Venturelli M, Layec G. Strategies targeting the NO pathway to counteract extra-pulmonary manifestations of COPD: A systematic review and meta-analysis. Nitric Oxide - Biology and Chemistry. 2022; 128: 59\u201371.","DOI":"10.1016\/j.niox.2022.08.004"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Yo C, Lee S, Chang S, Lee MC, Lee C. Value of high-sensitivity C-reactive protein assays in predicting atrial fibrillation recurrence: a systematic review and meta-analysis. BMJ Open. 2014; 4: e004418.","DOI":"10.1136\/bmjopen-2013-004418"},{"key":"ref42","unstructured":"Zhang L, Huang B, Scherlag BJ, Ritchey JW, Embi AA, Hu J, et al. Structural changes in the progression of atrial fibrillation: potential role of glycogen and fibrosis as perpetuating factors. International Journal of Clinical and Experimental Pathology. 2015; 8: 1712\u20131718."},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Grigoryan SV, Hazarapetyan LG, Adamyan KG. Myocardial fibrosis and atrial fibrillation. Russian Journal of Cardiology. 2018; 9; 71\u201376.","DOI":"10.15829\/1560-4071-2018-9-71-76"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Rong H, Huang L, Jin N, Hong J, Hu J, Wang S, et al. Elevated Homocysteine Levels Associated with Atrial Fibrillation and Recurrent Atrial Fibrillation. International Heart Journal. 2020; 61: 705\u2013712.","DOI":"10.1536\/ihj.20-099"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Hayashi H, Miyamoto A, Kawaguchi T, Naiki N, Xue JQ, Matsumoto T, et al. P-pulmonale and the development of atrial fibrillation. Circulation Journal. 2014; 78: 329\u2013337.","DOI":"10.1253\/circj.CJ-13-0654"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Cook DP, Xu M, Martucci VL, Annis JS, Aldrich MC, Hemnes AR, et al. Clinical insights into pulmonary hypertension in chronic obstructive pulmonary disease. Pulmonary Circulation. 2022; 12: e12006.","DOI":"10.1002\/pul2.12006"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Maraey AM, Maqsood MH, Khalil M, Hashim A, Elzanaty AM, Elsharnoby HR, et al. Impact of Chronic Obstructive Pulmonary Disease on Atrial Fibrillation Ablation Outcomes According to the National Readmission Database. The Journal of Innovations in Cardiac Rhythm Management. 2022; 13: 5112\u20135119.","DOI":"10.19102\/icrm.2022.130806"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstr\u00f6m-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. European Heart Journal. 2021; 42: 373\u2013498.","DOI":"10.1093\/eurheartj\/ehab648"},{"key":"ref49","unstructured":"Grigoryan SV, Hazarapetyan LG, Adamyan KG. The role of inflammation and fibrosis in the occurrence of atrial fibrillation in heart failure patients with mid-range ejection fraction. European Journal of Heart Failure. 2019; 21: 387."},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Brugada J, Katritsis DG, Arbelo E, Arribas F, Bax JJ, Blomstr\u00f6m-Lundqvist C, et al. 2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). European Heart Journal. 2020; 41: 655\u2013720.","DOI":"10.1093\/eurheartj\/ehz467"}],"container-title":["Reviews in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/24\/2\/10.31083\/j.rcm2402051","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T18:40:19Z","timestamp":1732732819000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/24\/2\/10.31083\/j.rcm2402051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,6]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"alternative-id":["S1530-6550(23)00861-X"],"URL":"https:\/\/doi.org\/10.31083\/j.rcm2402051","relation":{},"ISSN":["1530-6550","2153-8174"],"issn-type":[{"value":"1530-6550","type":"print"},{"value":"2153-8174","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,6]]},"article-number":"51"}}